Next year’s flu shot will shield only 20% against dominant strain

Recent doubts about traditional egg-based flu shots could mean more business for vaccines manufactured in cells. Protection against the dominant H3N2 flu strain offered by the coming season’s flu vaccine will still be far from optimal—putting it mildly. And that's thanks to the widely used manufacturing process based on eggs, a new study predicts.

• Source: fiercepharma
• 667
• April 24, 2018